Crescita Therapeutics Inc

Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Laval, Quebec and currently employs 65 full-time employees. The company went IPO on 2016-03-07. The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The company operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. The company also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment is engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. The Manufacturing and Services segment is engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.